- Home
- NUVL vs EAT Comparison
NUVL vs EAT Comparison
Compare NUVL & EAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- EAT
- Stock Information
- Founded
- NUVL 2017
- EAT 1975
- Country
- NUVL United States
- EAT United States
- Employees
- NUVL N/A
- EAT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- EAT Restaurants
- Sector
- NUVL Health Care
- EAT Consumer Discretionary
- Exchange
- NUVL Nasdaq
- EAT Nasdaq
- Market Cap
- NUVL 6.5B
- EAT 7.0B
- IPO Year
- NUVL 2021
- EAT N/A
- Fundamental
- Price
- NUVL $104.59
- EAT $112.36
- Analyst Decision
- NUVL Strong Buy
- EAT Buy
- Analyst Count
- NUVL 11
- EAT 15
- Target Price
- NUVL $121.45
- EAT $165.93
- AVG Volume (30 Days)
- NUVL 498.8K
- EAT 1.5M
- Earning Date
- NUVL 11-10-2025
- EAT 10-29-2025
- Dividend Yield
- NUVL N/A
- EAT N/A
- EPS Growth
- NUVL N/A
- EAT 136.76
- EPS
- NUVL N/A
- EAT 9.64
- Revenue
- NUVL N/A
- EAT $5,594,400,000.00
- Revenue This Year
- NUVL N/A
- EAT $7.11
- Revenue Next Year
- NUVL N/A
- EAT $5.12
- P/E Ratio
- NUVL N/A
- EAT $11.92
- Revenue Growth
- NUVL N/A
- EAT 23.18
- 52 Week Low
- NUVL $55.54
- EAT $95.60
- 52 Week High
- NUVL $103.69
- EAT $192.22
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- EAT 26.37
- Support Level
- NUVL $90.00
- EAT $124.00
- Resistance Level
- NUVL $99.94
- EAT $129.00
- Average True Range (ATR)
- NUVL 4.59
- EAT 5.10
- MACD
- NUVL 1.10
- EAT -0.76
- Stochastic Oscillator
- NUVL 100.00
- EAT 5.21
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About EAT Brinker International Inc.
Brinker International Inc operates casual dining restaurants under the brand's Chili Grill and Bar (Chili's) and Maggiano's Little Italy (Maggiano's). Chili's falls in the Bar and Grill category of casual dining. Its menu features Fresh Mex and Fresh Tex favorites including signature items such as slow-smoked baby back ribs, craft burgers, fajitas, and bottomless chips and salsa paired with tableside guacamole. Maggiano's is an Italian restaurant brand with a full lunch and dinner menu offering chef-prepared, such as appetizers, chicken, seafood, veal and prime steaks, and desserts. The company generates maximum revenue from Chili's segment.